Abstract: A membrane for corneal implant or keratoprosthesis comprising a biological polymer and a polyacrylamide is described. The mixture of both polymers produces a hydrogel that becomes a transparent film or membrane upon drying. The resulting device and tissue engineered implants are useful for biomedical applications of the cornea, such as tissue repair and transplantation.

Abstract: The invention provides an in vitro avascular human corneal equivalent that comprises immortalized human cell lines. As these corneal equivalents are in vitro models, they are maintained in an incubator throughout the testing period, thereby eliminating the problems and expense associated with animal care. The corneal equivalent is preferably surrounded by a matrix in which angiogenesis (formation of capillary-like structures) can occur in vitro. This surrounding matrix has the potential to play the role of a pseudo-sclera, allowing the in vitro assessment of the cornea's angiogenic reaction to any substance or injury. Furthermore, the model is capable of being produced easily, is physiologically functional and can give predictable and quantifiable results when submitted to various drugs, chemicals and/or physical trauma.

Abstract: Biomaterials like collagen can be designed for use as scaffolds for connective tissue reconstruction. It is known that proteins conjugated with PEGs exhibit a decrease in their biodegradation rate and their immunogenicity. Different concentrations and molecular weights of PEGs (PEG-750 and PEG-5000) were conjugated by chemical or irradiation means to collagen materials (films or sponges) which were then investigated by physicochemical assays, collagenase assay, fibroblast cell culture and subcutaneous implantation. PEG-conjugation delayed the degradation by collagenase and preserved a normal fibroblasts morphology and confluency in culture. In vivo, the porous structure of non-modified sponges was collapsed by day 15 with few observable fibroblasts between the collagen fibers. In PEG-modified collagen sponges, the porous structure remained stable for at least 30 days. Cell infiltration was particularly enhanced in PEG-750-conjugated collagen sponges.

Abstract: This invention relates to a biodegradable collagen matrix having a pore size and morphology which enhances the healing of a wound. It further relates to a process for preparing the matrix. One embodiment of the invention comprises a biodegradable matrix which comprises collagen, hyaluronic acid and fibronectin. Other embodiments include a process which comprises freeze drying a dispersion containing collagen, crosslinking the collagen via two crosslinking steps and freeze drying the crosslinked matrix.

Abstract: A therapeutic method for treating pressure ulcers like decubitus ulcers with biodegradable collagen flake compositions and with biodegradable collagen sponge or sponge-like compositions. The products of the invention includes biodegradable collagen flake compositions and biodegradable collagen sponge or sponge-like compositions. The products are useful for medical applications, like skin reconstruction, treatment of wounds, especially deep wounds, also in connection with surgery, including cosmetic surgery. The invention also deals with biocompatible synthetic resin sponge or sponge-like and flake products for medical and similar applications. The invention contemplates the treatment of human and animal species.